Abstract
Peripheral neuropathies are a group of disorders affecting peripheral nerves, characterized by either distal axonal degeneration or dysfunction of the ensheathing Schwann cells. Depending on the type of peripheral nerve involvement, there are many different symptoms and examination findings in patients with peripheral neuropathy. However, neuropathic pain is probably the single most prevalent complaint that results in consultation with a doctor. Although symptomatic therapies exist for treating pain in peripheral neuropathies (1), none are very effective or specific to the underlying pathogenic mechanisms, often resulting in too many side effects. There is a desperate need in the field to develop pathogenesis-based specific treatments to treat painful symptoms in patients with peripheral neuropathies. In PNAS, Hedstrom et al. present convincing preclinical data to show that enhancement of glial cell-line derived neurotrophic factor (GDNF) signaling with a small molecule agonist offers such a hope (2).
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
